Skin Fibrosis Treatment Market, by Drug Type (Corticosteroids, Antifibrotic, Immunotherapy Drugs, Other(Immunosuppressant)), by Route of Administration (Oral, Parenteral, Other(Topical)), by Application (Localized forms of scleroderma, Eosinophilic fasciitis, Scleromyxedema (papular mucinosis), and Scleredema), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Sep 2022

Code : CMI5255

Pages :156

Formats :

Excel and PDF

Industry : Pharmaceutical

Skin Fibrosis Treatment MarketSize and Trends

The global skin fibrosis treatment market is estimated to be valued at US$ 609.6 million in 2022 and is expected to exhibit a CAGR of 6.9% during the forecast period (2022-2030).

Figure 1. Global Skin Fibrosis Treatment Market Share (%), by Distribution Channel, 2022

Growing prevalence of systemic sclerosis which account one of the main cause for skin fibrosis among the population is expected to drive the global skin fibrosis treatment market.

The increasing prevalence of systemic sclerosis is expected to drive the market growth over the forecast period. For instance, in February 2021, according to data published by the BioMed Central Ltd, part of Springer Nature, prevalence of systemic sclerosis in Italy found out to be 22.2 per 100,000, with the highest prevalence observed for the cases aged ≥ 65 years. In females, SSc was predominant (86.7% on the total) with an overall sex ratio Female/Male of 6.5. Nevertheless, males presented a more severe disease, with a lower survival and notable differences in respiratory complications and metabolic comorbidities. According to the Center for Disease Control and Prevention, prevalence of systemic sclerosis in Europe and North America in 2019 was found to be 13.5-44.3 and 7.2-33.9 per 100,000 individuals.

Figure 2.Global Skin Fibrosis Treatment Market Value (US$ Million), by Region, 2022

Rise in research & development activities for the development of skin fibrosis drugs are expected to drive the market growth during the forecast period.

Increasing research and development activities by the key players in the market for the development of skin fibrosis drugs are expected to drive the market growth over the forecast period. For instance, on March 14, 2022, Chemomab Therapeutics, Ltd., a clinical-stage biotechnology company, was focused on development and discovery of ingenious therapeutics for fibrotic and inflammatory diseases with high unmet need. CM-101, was presented with patient sample data and preclinical data as a novel therapy for the treatment of systemic sclerosis.

Market- Trends